Statement re: Award of Invention of Innovation FAST Grant

DXS International

14/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230614:nGNE7K8MfH&default-theme=true


DXS INTERNATIONAL PLC

(AQSE: DXSP)

Award of Invention of Innovation FAST Grant

for Hypertension Management

DXS International plc (AQSE: DXSP) is pleased to announce that our ExpertCare
medicines optimisation tool has been awarded a £20,000 Invention for
Innovation (i4i) FAST (Funding At the Speed of Translation) grant from the
National Institute for Health and Care Research.

The project study will encompass the review of four hundred and eighty
diagnosed hypertensive patients across several participating GP practices to
answer the core question of ‘Does the use of ExpertCare in hypertension
medication reviews lead to an increase in the proportion of hypertensive
patients whose medication treatment is compliant with NICE guidelines?’.

The project research plan and outcomes are intended to verify the impact
ExpertCare achieved at the DXS pilot sites in 2021 and 2022 and could prove
pivotal in advancing the management of hypertensive patients.

Commenced on the 1(st) of May, the project is on target for completion by the
31(st) of August 2023. We are collaborating with the Eastern Academic Health
Science Network who will validate the trial data and publish the results.

David Immelman, CEO said. “This is an exciting opportunity as soon we will
have a formal evaluation by Eastern AHSN, of our ExpertCare hypertension
solution’s ability to assist GP practices improve NICE (National Institute
for Health and Care Excellence) compliance for hypertensive patients. Evidence
shows that improved NICE compliance will result in improved blood pressure
control which currently in England is only 60%. Improved blood pressure
control will result in reduced heart attacks and strokes saving lives and the
NHS money.”

The Directors of DXS International plc accept responsibility for this
announcement

Enquiries:

 David Immelman (Chief Executive) DXS International plc      01252 719800 david@dxs-systems.com  
 Wrecclesham House Wrecclesham Road Farnham Surrey GU10 4PS                                      
 www.dxs-systems.co.uk                                                                           



 Corporate Advisor                              
 David Papworth City & Merchant  0207 101 7676  



 Corporate Broker                                 
 Hybridan LLP Claire Louise Noyce  020 3764 2341  

Note to Editors:

DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other trusted NHS
sources, to doctors, nurses and pharmacists in their workflow and during the
patient consultation. This effective clinical decision support ultimately
translates to improved healthcare outcomes delivered more cost effectively
which should significantly contribute towards the NHS achieving its projected
efficiency savings